image
Healthcare - Biotechnology - NASDAQ - US
$ 7.62
-3.67 %
$ 177 M
Market Cap
-3.81
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Jun, 6, 2025.

The intrinsic value of one INMB stock under the worst case scenario is HIDDEN Compared to the current market price of 7.62 USD, INmune Bio, Inc. is HIDDEN

This DCF valuation model was last updated on Jun, 6, 2025.

The intrinsic value of one INMB stock under the base case scenario is HIDDEN Compared to the current market price of 7.62 USD, INmune Bio, Inc. is HIDDEN

This DCF valuation model was last updated on Jun, 6, 2025.

The intrinsic value of one INMB stock under the best case scenario is HIDDEN Compared to the current market price of 7.62 USD, INmune Bio, Inc. is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart INMB

image
$11.0$11.0$10.0$10.0$9.0$9.0$8.0$8.0$7.0$7.0$6.0$6.0$5.0$5.0$4.0$4.015 Dec15 DecJan '25Jan '2515 Jan15 JanFeb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '2515 Apr15 AprMay '25May '2515 May15 MayJun '25Jun '25
FINANCIALS
14 K REVENUE
-90.97%
-42.6 M OPERATING INCOME
-43.35%
-42.1 M NET INCOME
-40.24%
-33.4 M OPERATING CASH FLOW
-178.47%
0 INVESTING CASH FLOW
0.00%
18.2 M FINANCING CASH FLOW
531.03%
50 K REVENUE
0.00%
-9.9 M OPERATING INCOME
-4.63%
-9.74 M NET INCOME
-5.65%
-6.82 M OPERATING CASH FLOW
38.04%
0 INVESTING CASH FLOW
0.00%
5.27 M FINANCING CASH FLOW
353.80%
Balance Sheet INmune Bio, Inc.
image
Current Assets 22.7 M
Cash & Short-Term Investments 20.9 M
Receivables 1.41 M
Other Current Assets 331 K
Non-Current Assets 16.9 M
Long-Term Investments 0
PP&E 307 K
Other Non-Current Assets 16.6 M
52.88 %3.56 %41.94 %Total Assets$39.6m
Current Liabilities 7.22 M
Accounts Payable 6.56 M
Short-Term Debt 140 K
Other Current Liabilities 517 K
Non-Current Liabilities 244 K
Long-Term Debt 244 K
Other Non-Current Liabilities 0
87.93 %6.93 %3.27 %Total Liabilities$7.5m
EFFICIENCY
Earnings Waterfall INmune Bio, Inc.
image
Revenue 14 K
Cost Of Revenue 0
Gross Profit 14 K
Operating Expenses 42.6 M
Operating Income -42.6 M
Other Expenses -553 K
Net Income -42.1 M
5m5m00(5m)(5m)(10m)(10m)(15m)(15m)(20m)(20m)(25m)(25m)(30m)(30m)(35m)(35m)(40m)(40m)(45m)(45m)14k014k(43m)(43m)553k(42m)RevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
100.00% GROSS MARGIN
100.00%
-304535.71% OPERATING MARGIN
-304535.71%
-300585.71% NET MARGIN
-300585.71%
-131.11% ROE
-131.11%
-106.37% ROA
-106.37%
-131.26% ROIC
-131.26%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis INmune Bio, Inc.
image
00(5m)(5m)(10m)(10m)(15m)(15m)(20m)(20m)(25m)(25m)(30m)(30m)(35m)(35m)(40m)(40m)(45m)(45m)20162016201720172018201820192019202020202021202120222022202320232024202420252025
Net Income -42.1 M
Depreciation & Amortization 553 K
Capital Expenditures 0
Stock-Based Compensation 7.6 M
Change in Working Capital 1.04 M
Others 1.46 M
Free Cash Flow -33.4 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets INmune Bio, Inc.
image
Wall Street analysts predict an average 1-year price target for INMB of $22 , with forecasts ranging from a low of $22 to a high of $22 .
INMB Lowest Price Target Wall Street Target
22 USD 188.71%
INMB Average Price Target Wall Street Target
22 USD 188.71%
INMB Highest Price Target Wall Street Target
22 USD 188.71%
Price
Max Price Target
Min Price Target
Average Price Target
2222202018181616141412121010886644Jul '24Jul '24Aug '24Aug '24Oct '24Oct '24Nov '24Nov '2420252025Feb '25Feb '25Apr '25Apr '25Jun '25Jun '25Jul '25Jul '25Aug '25Aug '25Oct '25Oct '25Nov '25Nov '2520262026Feb '26Feb '26Apr '26Apr '26Jun '26Jun '26
4. DIVIDEND ANALYSIS
5. COMPETITION
slide 2 of 12
6. Ownership
Insider Ownership INmune Bio, Inc.
image
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
52.9 K USD 1
6-9 MONTHS
331 K USD 3
9-12 MONTHS
7. News
INmune Bio: XPro Trial Readout In Alzheimer's Disease Offers Big Opportunity I rate INmune Bio, Inc. a speculative Strong Buy for high-risk investors, hinging on XPro's upcoming Phase II results in early Alzheimer's disease. XPro's unique mechanism targets neuroinflammation without ARIA risk, potentially serving 70% of early AD patients and outperforming current therapies. INMB's short cash runway makes positive XPro data critical for future funding, partnerships, or acquisition; failure could force shareholder dilution. seekingalpha.com - 1 month ago
INmune Bio, Inc. (INMB) Q1 2025 Earnings Call Transcript INmune Bio, Inc. (NASDAQ:INMB ) Q1 2025 Earnings Conference Call May 8, 2025 4:30 PM ET Company Participants David Moss - Chief Financial Officer Dr. RJ Tesi - Chief Executive Officer Dr. Mark Lowdell - Chief Scientific Officer Dr. CJ Barnum - Head, Neuroscience Conference Call Participants Denis Reznik - Raymond James George Farmer - Scotiabank Tom Shrader - BTIG Laura Suriel - Alliance Global Partners Operator Greetings. And welcome to the INmune Bio First Quarter 2025 Earnings Call. seekingalpha.com - 1 month ago
INmune Bio Inc. Announces First Quarter 2025 Results and Provides Business Update BOCA RATON, Fla., May 08, 2025 (GLOBE NEWSWIRE) -- INmune Bio Inc.  (NASDAQ: INMB) (the “Company”), a clinical-stage biotechnology company targeting inflammation and immunology through the innate immune system, today announces its financial results for the quarter ended March 31, 2025 and provides a business update. globenewswire.com - 1 month ago
INmune Bio Inc. to Report First Quarter 2025 Financial Results and Provide Corporate Update on Thursday, May 8th Boca Raton, Florida, May 05, 2025 (GLOBE NEWSWIRE) --   INmune Bio Inc . (NASDAQ: INMB) (the “Company”), a clinical-stage inflammation and immunology company targeting microglial activation and neuroinflammation as a cause of Alzheimer's Disease (AD), today announced that it will host a conference call on Thursday, May 8th, 2025 at 4:30pm EDT to discuss results for its quarter ended March 31, 2025 and to provide a corporate update. globenewswire.com - 1 month ago
INmune Bio Partners with Cell and Gene Therapy Catapult to Scale Up CORDStrom™ Manufacturing for Commercial Readiness Stevenage, UK, and Boca Raton, Florida, US, April 14, 2025 (GLOBE NEWSWIRE) --  INmune Bio Inc. (NASDAQ: INMB) a clinical-stage biotechnology company targeting inflammation and immunology through the innate immune system has partnered with the Cell and Gene Therapy Catapult (CGT Catapult) to establish large-scale, commercial-ready manufacturing for its cell therapy platforms. CGT Catapult is an independent technology and innovation organization specializing in the advancement of the cell and gene therapy industry. It was established by and works in partnership with Innovate UK. globenewswire.com - 2 months ago
INmune Bio, Inc. (INMB) Q4 2024 Earnings Call Transcript INmune Bio, Inc. (NASDAQ:INMB ) Q4 2024 Results Conference Call March 27, 2025 4:30 PM ET Company Participants David Moss - CFO Raymond Tesi - CEO & Co-Founder Mark Lowdell - Chief Scientific Officer Christopher Barnum - Head of Neuroscience Conference Call Participants George Farmer - Scotiabank Thomas Shrader - BTIG Denis Reznik - Raymond James Elemer Piros - Rodman James Molloy - Alliance Global Partners Operator Greetings, and welcome to the INmune Bio's. 2024 Fourth Quarter and Full Year Earnings Call. seekingalpha.com - 2 months ago
INmune Bio Inc. Announces Year End 2024 Results and Provides a Business Update BOCA RATON, Fla., March 27, 2025 (GLOBE NEWSWIRE) -- INmune Bio Inc.  (NASDAQ: INMB) (the “Company”), a clinical-stage inflammation and immunology company focused on developing treatments that harness the patient's innate immune system to fight disease, today announces its financial results for the year ended December 31, 2024 and provides a business update. globenewswire.com - 2 months ago
Undercovered Dozen: INmune Bio, Primerica, First Quantum, Pinnacle West + The 'Undercovered' Dozen series highlights 12 lesser-covered stocks, offering fresh ideas and fostering discussion among investors. Mitsui & Co. is given a 'buy' recommendation, driven by Warren Buffett's increased stake, stable commodity prices, and promising long-term growth from a new Australian iron ore deal. Sandisk Corporation is also seen as a 'buy' post-separation from Western Digital, with strong market performance and potential for unlocking shareholder value as an independent flash storage company. seekingalpha.com - 2 months ago
INmune Bio: CORDstrom Is A Game-Changer, As Investors Await Alzheimer's Results INmune Bio's CORDstrom for RDEB shows promising results, supported by FDA designations, and could lead to a 9.8x stock revaluation. XPro for Alzheimer's has significant potential, with a $24.76 billion valuation if successful, offering a 135x stock upside. CORDstrom may act as a fail-safe for INmune Bio's stock if XPro fails, ensuring a high likelihood of substantial returns. seekingalpha.com - 3 months ago
INmune Bio Opens Phase II in High Dose Cohort of INKmune™ Trial in Prostate Cancer BOCA RATON, Fla, Feb. 12, 2025 (GLOBE NEWSWIRE) --   INmune Bio Inc. (NASDAQ: INMB) (the "Company"), a clinical-stage immunology and inflammation company, continues to advance its Natural Killer (NK) cell therapy, INKmune™, in a Phase I/II trial (the “CaRe PC” trial) for men with metastatic castration-resistant prostate cancer (mCRPC). The Company is pleased to announce completion of the third and highest dose cohort of the Phase I portion of the trial allowing opening of the Phase II high dose cohort. globenewswire.com - 4 months ago
INmune Bio Announces Plan to Submit FDA Biologics License Application (BLA) Seeking Approval of CORDStrom for Treatment of Recessive Dystrophic Epidermolysis Bullosa (RDEB) Boca Raton, Florida, Feb. 10, 2025 (GLOBE NEWSWIRE) -- INmune Bio, Inc.   (NASDAQ: INMB) (the “Company”) , a clinical-stage inflammation and immunology company focused on developing treatments that harness the patient's innate immune system to fight disease, announced today, following a Type C meeting with the U.S. Food and Drug Administration (FDA), its intent to submit a BLA in the US and Marketing Authorization Application (MAA) in the UK and EU supported by data from the MissionEB clinical trial investigating CORDStrom as a disease-modifying therapy for treating RDEB in pediatric patients. globenewswire.com - 4 months ago
INmune Bio: Phase 2 Trial In Alzheimer's Disease Is My Highest Risk-Reward Bet Of 2025 INmune Bio's XPro targets neuroinflammation, showing promising biomarker results in Alzheimer's, with a potential to outperform current treatments and attract big pharma interest. The Phase 2 trial for XPro in Alzheimer's is fully enrolled, with topline data expected around May-June 2025, marking a pivotal moment. XPro's selective TNF inhibition has shown significant reductions in key biomarkers like ptau-217 and neurofilament light, indicating strong efficacy in neurodegenerative diseases. seekingalpha.com - 5 months ago
8. Profile Summary

INmune Bio, Inc. INMB

image
COUNTRY US
INDUSTRY Biotechnology
MARKET CAP $ 177 M
Dividend Yield 0.00%
Description INmune Bio, Inc., a clinical-stage immunotherapy company, focuses on developing drugs to reprogram the patient's innate immune system to treat disease. The company develops and commercializes product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. Its development programs include INKmune, which focuses on treating women with relapse refractory ovarian carcinoma and patients with high-risk myelodysplastic syndrome; INB03, an immunotherapy that treats patients with hematologic malignancies and solid tumors; and XPro1595 for the treatment of Alzheimer's disease. The company has license agreements with Xencor, Inc.; Immune Ventures, LLC; University of Pittsburg; and University College London. INmune Bio, Inc. was incorporated in 2015 and is headquartered in Boca Raton, Florida.
Contact 225 NE Mizner Boulevard, Boca Raton, FL, 33432 https://www.inmunebio.com
IPO Date Feb. 4, 2019
Employees 13
Officers Dr. Mark William Lowdell Ph.D. Chief Scientific Officer & Chief Manufacturing Officer Dr. Raymond Joseph Tesi M.D. Co-Founder, President, Chief Executive Officer, Chief Medical Officer & Chairman Mr. David J. Moss M.B.A. Chief Financial Officer, Treasurer & Secretary Mr. Joshua S. Schoonover Esq. General Counsel